ImaginAb and PharmaLogic Enter into Manufacturing and Distribution Agreement for CD8 ImmunoPET agent Zirconium 89 Crefmirlimab Berdoxam in USA

Inglewood, California, June 10th 2022 – ImaginAb, Inc., a market leading global biotechnology company focused on developing next generation ImmunoPET imaging agents and therapeutic radiopharmaceuticals (RPT) is pleased to announce the completion of a Master Services Agreement for the commercial manufacturing and distribution of its CD8 ImmunoPET agent zirconium Zr 89 crefmirlimab berdoxam in the USA with PharmaLogic Corp. (Boca Raton, FL).

Under the agreement PharmaLogic will initially supply patient-specific unit doses from its Denver, CO based radiopharmacy before expanding to select sites across their network of over 30 locations across the United States and Puerto Rico.

Ian Wilson, Chief Executive Officer of ImaginAb said: “We are very pleased to be working with PharmaLogic to manufacture zirconium Zr 89 crefmirlimab berdoxam in the USA. We’ve chosen to work with the PharmaLogic team because of their experience, class leading track-record of delivering product and their continued growth and investment in radiopharmaceutical manufacturing infrastructure.”

PharmaLogic President and CEO Steve Chilinski said: “PharmaLogic is proud to partner with ImaginAb to make zirconium Zr 89 crefmirlimab berdoxam available in the US. The cornerstone of our company is to support the development and commercialization of breakthrough radiopharmaceuticals for the diagnosis and treatment of disease”.

About ImaginAb

ImaginAb Inc. is a biotechnology company focused on developing radiopharmaceutical imaging and therapy agents. ImaginAb engineer’s antibody fragments called minibodies that maintain the exquisite specificity of full-length antibodies while remaining biologically inert in the body. Used with widely available PET Imaging technology and therapeutic isotopes, these novel minibodies bind specifically to cell surface targets, providing physicians with a whole-body picture of immune activity and the potential to treat cancer.

ImaginAb is advancing a pipeline of minibodies against both oncology and immunology targets. The company is backed by top tier venture capital firms and strategic corporate firms including, Adage Capital, The Cycad Group, Norgine Ventures, TRC, Jim Pallotta of the Raptor Group, The Parker Institute for Cancer Immunotherapy, and Merck (MSD) Pharma. For more information about ImaginAb’s pipeline and technology, visit www.imaginab.com.
About CD8 ImmunoPET

The 89Zr CD8 ImmunoPET technology (zirconium Zr 89 crefmirlimab berdoxam) is a [89Zr]-labelled minibody that binds the CD8 receptor on human T cells and is used for quantitative, non-invasive PET imaging of CD8+ cells in patients. CD8+ cells are the main effector cells involved in the immune response against tumor cells induced by immunotherapies and they also play a key role in multiple autoimmune diseases. As such, quantitative imaging of CD8+ cells can be used to diagnose the immune status of a patient, to measure the efficacy of immunotherapies and predict patient outcomes.

About PharmaLogic

PharmaLogic Holdings Corp., founded in 1993, is an innovative and reliable supplier of radiopharmaceuticals. With over 900 employees currently operating 39 facilities, PharmaLogic is the fastest growing radiopharmaceutical manufacturer in North America. PharmaLogic is privately held and backed by Webster Equity Partners and MedEquity Capital. PharmaLogic has established itself as the CDMO of choice to the radiopharmaceutical industry for its expertise in drug development, manufacturing, and distribution for clinical trials and commercial supply.

For further information please contact:

**ImaginAb**

Ian Wilson  
CEO  
Email: info@imaginab.com  
Phone: +1 310 645 1211

**PharmaLogic**

Scott Holbrook  
Chief Strategy Officer, Chief Strategy Officer, General Manager PET & Precision Medicine  
Email: sholbrook@radiopharmacy.com  
+1 561 416 0085